证券代码：600129 证券简称：太极集团 公告编号：2025-047 重庆太极实业（集团）股份有限公司 关于增补董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）于 2025 年 7 月 7 日召开了第十届董事会第二十九次会议，审议通过了《关于 增补公司董事的议案》。 根据《公司法》和《公司章程》的有关规定，经公司控股股东太 极集团有限公司推荐，同意余星玥女士作为公司第十届董事会董事候 选人，任期自股东大会审议通过之日起至第十届董事会届满时止（简 历附后）。 附：余星玥女士个人简历 上述议案在提交董事会审议前，已经公司第十届董事会提名委员 会会议审议通过。 余星玥，女，1988 年出生，中共党员，重庆交通大学机械设计 制造及自动化/工程造价管理专业本科，高级经济师、二级建造师。 曾任重庆市涪陵国有资产投资经营集团有限公司项目管理部副经理， 现任重庆市涪陵国有资产投资经营集团有限公司项目管理部经理。 截至本公告披露日，余星玥女士未持有公司股份；与公司董事、 监事、高 ...

证券代码：600129 证券简称：太极集团 公告编号：2025-045 重庆太极实业（集团）股份有限公司 第十届监事会第二十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）第十届监 事会第二十四次会议于 2025 年 6 月 27 日以邮件方式发出书面通知， 于 2025 年 7 月 7 日以现场及视频方式召开。会议应到监事 3 人，实到 监事 3 人，公司董事会秘书列席了会议。本次会议的召集、召开程序符 合《公司法》和《公司章程》的有关规定，会议合法有效。会议审议并 通过了如下议案： 一、关于变更会计师事务所的议案（具体内容详见公司披露的《关 于变更会计师事务所的公告》；公告编号 2025-046） 鉴于原审计机构天健会计师事务所（特殊普通合伙）服务期限已 满，根据《国有企业、上市公司选聘会计师事务所管理办法》（财会 〔2023〕4 号）等相关规定，为保证审计工作的独立性和客观性，经 公司邀请招标，拟聘任立信会计师事务所（特殊普通合伙）为公司 2025 年 ...

Core Viewpoint - China National Pharmaceutical Group Corporation (Sinopharm Group) is facing significant challenges with Taiji Group, which has experienced a dramatic decline in performance after a strong 2023, with a 20.72% drop in revenue and a 96.76% plunge in net profit in 2024 [1][3][9] Financial Performance - In 2024, Taiji Group's total revenue decreased by 20.72% to 12.386 billion yuan, while net profit fell by 96.76% to 26.6527 million yuan [1][3] - The company's net profit for 2024 was revised to reflect a 96.76% decline, significantly impacted by tax liabilities from subsidiaries [9][10] - Quarterly performance showed a severe drop in net profit, particularly in Q4, which contributed to the overall annual decline [4][5] Product Performance - Key products like Huoxiang Zhengqi Oral Liquid saw a sharp decline in sales, with 2024 sales volumes dropping to 96 million boxes from 231 million boxes in 2023 [8] - Other products also experienced significant sales declines, while only a few, such as sinusitis oral liquid, showed growth [8] Management and Governance - Recent personnel changes in the board of directors, with several resignations and new appointments from Sinopharm Group, indicate a shift in management strategy [5][6] - The effectiveness of the new management in reversing the company's fortunes remains uncertain as the deadline for resolving industry competition issues approaches [10] Strategic Challenges - The company is struggling with an aging product portfolio and has not introduced new blockbuster drugs in over a decade, relying heavily on existing products [8] - The upcoming deadline for Sinopharm Group's commitment to resolve competition issues poses additional pressure on Taiji Group to meet its revenue targets for the 14th Five-Year Plan [10]

Group 1 - The "Hundred Days of Millions Recruitment" initiative launched four online recruitment events focusing on state-owned enterprises, the new energy sector, the pharmaceutical and healthcare industry, and internships, with over 3,900 participating employers and a recruitment demand exceeding 26,000 positions [1][2] - The state-owned enterprise recruitment event, organized by China Intelligent Recruitment Network, involved 121 employers including China Star Network Group and Nanguang Group, with a recruitment demand of over 2,100 positions for roles such as digital engineers and financial auditors [1] - The new energy sector recruitment event, hosted by Tongdao Recruitment Group, included over 1,500 employers like Trina Solar and LONGi Green Energy, with a demand for more than 5,500 positions for roles such as senior control engineers and photovoltaic channel sales [1] Group 2 - The pharmaceutical and healthcare recruitment event, organized by Medical Pulse Recruitment Platform, featured over 2,000 employers including Guangdong Tianpu Biochemical and Jiangsu Xincheng Health, with a recruitment demand exceeding 13,000 positions for roles such as medical representatives and clinical sales representatives [1] - The internship recruitment event, managed by Guopin Recruitment Platform, involved 286 employers including Dongfeng Motor and China Energy Conservation, with a demand for over 5,600 positions for roles such as strategic research and new media operations [2] - Employers and job seekers can access the recruitment events through platforms like China Public Recruitment Network and China National Talent Network [2]

Group 1 - Shanghai Municipal Medical Procurement Management Office has suspended the procurement qualifications for two drugs due to non-compliance with price adjustment requirements: hydrochloride dobutamine injection produced by Anhui Changjiang Pharmaceutical Co., Ltd. and hydrochloride arginine injection produced by Jilin Huinan Changlong Biochemical Pharmaceutical Co., Ltd [1] - Both drugs are classified as shortage drugs, with multiple companies having obtained approval numbers for these products in China [1] - The national average price for hydrochloride dobutamine injection (2ml:20mg) is reported at 3.53 yuan per unit, while hydrochloride arginine injection (20ml:5g) is at 11.68 yuan per unit [1] Group 2 - The management mechanism for shortage drugs in China is improving, with the State Council issuing opinions in 2019 to ensure the supply and price stability of these drugs [2] - The average delivery rate for drugs on the national shortage list has increased from approximately 60% before 2019 to 90% currently [2] - New issues have emerged, including some companies creating artificial shortages to justify price increases, particularly at the local level [2] Group 3 - In August 2024, several national departments issued a notice to strengthen monitoring of production reserves for shortage drugs and those selected for centralized procurement [3] - A total of 109 shortage drug formulations, 60 raw materials, and 240 nationally selected drugs are under production reserve monitoring, with dynamic adjustments to the monitoring list [3] - The National Medical Insurance Administration has issued guidelines for risk management of shortage drug prices, focusing on price information disclosure, analysis, and monitoring [3]

Core Viewpoint - The company, Taiji Group, is facing significant challenges, including a substantial decline in stock price and concerns regarding management's effectiveness in addressing competition and improving performance [2][3]. Group 1: Stock Performance - As of June 27, 2025, Taiji Group's stock closed at 21.22 yuan, down 0.52%, with a turnover rate of 1.49% and a trading volume of 83,100 shares, amounting to a transaction value of 177 million yuan [1]. - Over the past year and a half, the stock price has decreased by more than 70% [3]. Group 2: Management and Strategy - The management team is focusing on a strategy of "two focuses, two innovations" aimed at strengthening and optimizing major traditional Chinese medicine products, emphasizing technological and marketing innovations to drive performance recovery [2]. - The actual controller of the company has committed to resolving competition issues through various means, including asset swaps and management changes, while ensuring no new competition arises [3]. Group 3: Investor Communication - The company adheres to information confidentiality and fairness principles, stating that shareholder numbers and major shareholders will only be disclosed in regular reports [2]. - The company has received inquiries from investors regarding the management's actions and the commitment to resolving competition issues, indicating a need for clearer communication and transparency [3]. Group 4: Trading Information - On June 27, the net outflow of main funds was 18.81 million yuan, accounting for 10.64% of the total transaction value [4]. - Retail investors showed a net inflow of 3.59 million yuan, representing 2.03% of the total transaction value [5].

| 000538 | 云南白药 | -0.02 | 0.29 | -464.02 | | --- | --- | --- | --- | --- | | 603195 | 公牛集团 | -3.31 | 0.27 | -294.27 | | 000599 | 青岛双星 | 1.20 | 1.94 | -269.88 | | 603031 | 安孚科技 | 0.68 | 0.92 | -259.74 | | 603043 | 广州酒家 | -0.84 | 0.32 | -234.96 | | 002820 | 桂发祥 | 2.19 | 2.89 | -64.03 | | 600305 | 恒顺醋业 | 0.26 | 0.46 | 1.38 | | 603156 | 养元饮品 | -1.67 | 0.17 | 8.65 | | 001328 | 登康口腔 | 2.08 | 5.37 | 12.71 | | 002568 | 百润股份 | 0.53 | 1.34 | 13.18 | | 300999 | 金龙鱼 | 0.94 | 0.78 | 37.38 | | 000100 | TCL科技 | -0.46 | 0. ...

证券代码：600129 证券简称：太极集团 公告编号：2025-043 重庆太极实业（集团）股份有限公司 关于获得政府补助的公告 特此公告。 重庆太极实业（集团）股份有限公司 2025 年 6 月 18 日 近日，重庆太极实业（集团）股份有限公司（以下简称：公司） 控股子公司太极集团重庆桐君阁药厂有限公司收到与收益相关的政 府补助 2,000 万元，占公司 2024 年度归属于上市公司股东净利润的 75.04%。 二、补助的类型及其对上市公司的影响 根据《企业会计准则第 16 号-政府补助》的相关规定，上述政府 补助款项属于与收益相关的政府补助，将对公司 2025 年度的净利润 产生积极影响，具体会计处理及其对公司利润的影响，最终以会计师 事务所审计确认后的结果为准。敬请广大投资者注意投资风险。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 一、获得补助的基本情况 ...

Group 1 - Company Xi Zhong Technology proposed to repurchase shares worth between 75 million and 150 million yuan using excess funds and self-owned funds [1] - Company Yongxi Electronics expects a revenue growth of 16.6% to 28.88% in the first half of the year, with projected revenue between 1.9 billion and 2.1 billion yuan [2] - Company Jingyi Equipment anticipates a revenue increase of 36.54% to 42.48%, with expected revenue between 690 million and 720 million yuan [2][3] Group 2 - Company Haipuri received approval from the European Medicines Agency (EMA) for a new production line for Enoxaparin Sodium injection, with an annual capacity of 330 million doses [4] - Company Inner Mongolia Xinhua plans to merge its wholly-owned subsidiaries to optimize resource allocation and improve operational efficiency [5] - Company Cloud Chemical intends to sign daily related transaction framework agreements with its controlling shareholder to reduce operational costs [7] Group 3 - Company China Software received approval from the China Securities Regulatory Commission for a specific stock issuance [8] - Company Wankong Intelligent's subsidiary won a bid for a project with the State Grid worth approximately 12.17 million yuan [9] - Company Lianlong obtained a patent for an anti-aging agent, which is expected to enhance its product offerings in polymer materials [11] Group 4 - Company Yunlu plans to increase its shares by 4 million to 12 million yuan through stock purchases by its executives [12] - Company Enhua Pharmaceutical's chairman increased his stake by 237,900 shares [14] - Company Daqin Railway announced the resignation of its general manager due to retirement [15] Group 5 - Company Hefei Urban Construction signed a land use rights transfer contract for an industrial site with an area of 78,561.78 square meters, with a payment of 103 million yuan due by July 13, 2025 [16] - Company Taiji Group received a government subsidy of 20 million yuan, representing 75.04% of its projected net profit for 2024 [17] - Company Guodian Nanrui elected a new chairman, Zheng Zongqiang, while he resigned from his previous roles [19] Group 6 - Company Xinhua Medical received a medical device registration certificate for a thromboelastography testing kit [20] - Company Baotailong's subsidiary obtained a mining license for a graphite mine with a production capacity of 2 million tons per year [21] - Company Zejing Pharmaceutical received approval for clinical trials of its innovative cancer treatment drugs [22] Group 7 - Company Aojing Medical's artificial bone repair material received registration approval in Vietnam [23] - Company Chengjian Development received a cash dividend of 90.2169 million yuan from Guoxin Securities [24] - Company Rili Technology proposed a share repurchase plan worth between 10 million and 20 million yuan [25] Group 8 - Company Deshi General Institute received approval to issue up to 1 billion yuan in technology innovation bonds [44] - Company Tongding Interconnect plans to bid for two procurement projects worth approximately 717 million yuan [46] - Company Bangji Technology plans to acquire multiple agricultural companies [46]

Core Viewpoint - The Chinese government is optimizing the centralized procurement policy for drugs and medical supplies to ensure quality and affordability for the public, indicating potential issues with the quality of some procured drugs and the need for further exploration of the policy [1][2][3]. Group 1: Policy Optimization - The State Council is focusing on enhancing the evaluation of drug procurement policies and ensuring the quality of drugs and medical supplies [1][2]. - The 11th batch of drug procurement is expected to take place in 2025, with a target of 700 varieties to be procured [1]. - The introduction of a new pricing mechanism aims to prevent extreme low pricing that could harm consumer confidence and the survival of companies [3][4]. Group 2: Pricing Mechanism Adjustments - The new draft policy suggests a price difference limit of 1.8 times the lowest bid for the same drug, with a focus on avoiding abnormal low pricing [4]. - The extreme low prices observed in recent procurements have raised concerns about their sustainability and potential negative impacts on the pharmaceutical industry [3][7]. - The rapid increase in B-license companies, which do not produce drugs themselves, has led to concerns about quality and market stability [7][8]. Group 3: Quality Assurance - Discussions around the relationship between low prices and drug quality have intensified, especially following the disqualification of a company for failing to meet quality standards [6][7]. - The government emphasizes the need for a transparent regulatory mechanism to ensure drug quality while maintaining competitive pricing [5][6]. - The focus on quality is crucial as low prices could lead to reduced profit margins for manufacturers, potentially impacting their ability to maintain quality and innovate [7][8]. Group 4: Future Directions - The upcoming 11th batch of procurement is seen as a significant reform, reflecting lessons learned from previous rounds and aiming for a more balanced approach to pricing and quality [10][11]. - There is a call for a unified and transparent procurement platform to ensure fair pricing and quality assurance in drug procurement [10][11]. - The need to balance innovation and quality in drug procurement is highlighted, with suggestions to incorporate clinical benefits into the procurement evaluation criteria [11].